News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|May 23, 2024

Narcolepsy Evaluation, Management, and Treatment Considerations

Focusing on the evaluation and management of narcolepsy, experts provide insights on clinical assessment practices and treatment classes.

Episodes in this series

Video 1 - "Definition of Narcolepsy and Unmet Needs"

EP. 1 Definition of Narcolepsy and Unmet Needs

Video 2 - "Pathophysiology of Narcolepsy and the Role of Orexins"

EP. 2 Pathophysiology of Narcolepsy and the Role of Orexins

Video 2 - "Diagnostic Practices for Narcolepsy"

EP. 3 Diagnostic Practices for Narcolepsy

Video 2 - "Narcolepsy Evaluation, Management, and Treatment Considerations"

EP. 4 Narcolepsy Evaluation, Management, and Treatment Considerations

Video 5 - "Clinical Treatment Strategies for a Patient Suffering from EDS and Hypnagogic Hallucinations"

EP. 5 Clinical Treatment Strategies for a Patient Suffering from EDS and Hypnagogic Hallucinations

Video 6 - "Patient-Centered Approach: Adapting Narcolepsy Treatments to Address Adverse Events and Mitigate Misuse Risks"

EP. 6 Patient-Centered Approach: Adapting Narcolepsy Treatments to Address Adverse Events and Mitigate Misuse Risks

Video 7 - "Complex Case of a 23-Year-Old Male College Student Suffering From Narcolepsy Symptoms"

EP. 7 Complex Case of a 23-Year-Old Male College Student Suffering From Narcolepsy Symptoms

Video 8 - "Treatment Augmentation in a Patient with Narcolepsy and ADHD"

EP. 8 Treatment Augmentation in a Patient with Narcolepsy and ADHD

Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA

EP. 9 Considerations for the Management of Pediatric Patients with Narcolepsy

Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA

EP. 10 Non-Pharmacologic Interventions for Pediatric Patients with Narcolepsy

Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA

EP. 11 Clinical Pearls for the Management of Patients Suffering from Narcolepsy

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Concluding Thoughts: Practical Tips, Resources, and More

ByJonathan M. Meyer, MD, DLFAPA

December 8th 2025

A New Option: Getting TDM Data Faster

ByJonathan M. Meyer, MD, DLFAPA

December 1st 2025

Using TDMs to Improve Care and Communication

ByJonathan M. Meyer, MD, DLFAPA

November 20th 2025

Why Therapeutic Drug Monitoring Is Important for Antipsychotics

ByJonathan M. Meyer, MD, DLFAPA

November 13th 2025

1 KOL is featured in this series

Future Directions For Prescription Digital Therapeutics

ByGustavo Alva, MD, DFAPA,Erin Crown, MHS, PA-C, Psych-CAQ,Linda Trinh, DNP, MPH, FNP-C, PMHNP-BC

September 30th 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

December 4-5, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

Analyzing a Randomized Controlled Trial

In Memoriam: Two of Milwaukee’s Finest Psychiatrists, Jon Gudeman, MD, and Scott Sandage, MD

CAPS: A New Program to Support Early Intervention in Patients at Risk for Suicide

Case-Based Clinical Explorations in Schizophrenia

Fasedienol for Social Anxiety Disorder Does Not Demonstrate Significant Improvement in Phase 3 Study